Jun Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Zhu has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- George McDonald Church
Department of Genetics, Harvard Medical School, Boston, MA, USA
2 shared publications - Adrian R. Krainer
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724, USA
1 shared publication - Alexander van Oudenaarden
Department of Physics, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
1 shared publication Bin Xie
Center for the Study of Biological Complexity, Virginia Commonwealth University, Richmond, VA 23284, USA
1 shared publicationBradley T. Hyman
Department of Neurology, MassGeneral Institute for Neurodegenerative Disease (MIND), Charlestown, Massachusetts, USA
1 shared publicationC J Wu
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA
1 shared publication
Latest Publications
- 1 April 2010
- Published by Elsevier in Molecular Cell
- Vol. 38 (1) , 67-77
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
- 1 April 2010
- Published by Elsevier in Molecular Cell
- Vol. 38 (1) , 67-77
A Splicing-Independent Function of SF2/ASF in MicroRNA Processing
- Open Access
- 6 August 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (6) , 775-782
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10−4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.
- 6 August 2007
- Published by Springer Nature in Oncogene
- Vol. 27 (6) , 775-782
Open AccessQuantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors
Resistance to molecularly targeted chemotherapy, and the development of novel agents that are active against resistant forms of target proteins create the need for a sensitive and quantitative assay to monitor drug-resistant mutations in patients to guide treatment and assess response. Here, we describe an application of the polymerase colony (polony) method to identify and quantify known point mutations in the BCR-ABL oncogene in patients with chronic myelogenous leukemia who evolve resistance to ABL kinase inhibitors. The assay can detect mutations with a sensitivity of 10−4, quantify the burden of drug-resistant cells, and simultaneously monitor the dynamics of several coexisting mutations. As a proof of concept, we analysed blood samples from three patients undergoing therapy with ABL kinase inhibitors and found that the patients' response to therapy correlated with our molecular monitoring. We were also able to detect mutations emerging in patients long before clinical relapse. Therefore, the polony assay could be applied to a larger patient sample to assess the utility of early mutation detection in patient-specific treatment decisions. Finally, this methodology could be a valuable research tool to shed light on the natural behavior of mutations pre-existing kinase inhibitors therapy and either disappearing over time or slowly taking over.
- 26 July 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 103 (3) , 1228-1236
Single molecule profiling of tau gene expression in Alzheimer’s disease
Tau is a microtubule‐associated protein that is important for establishing and maintaining neuronal morphology. In addition to its role in normal cells, tau protein is involved in many neurodegenerative diseases, e.g. Alzheimer’s disease (AD) and frontotemporal dementia, as the main component of intraneuronal aggregates. Alternative splicing of tau gene in the brain can give rise to at least six protein variants. A causative role of skewed tau exon 10 inclusion has been defined in frontotemporal dementia; however, no link was established between the aberrant splicing of tau and AD. Here, we applied a single‐molecule‐based technology, polymerase colony or polony, to simultaneously monitor tau splicing variant and haplotype profile in sporadic AD and normal brains. We found that the coordinated expression of tau exons 2 and 10 is altered in AD. Additional investigations of cis and trans mechanisms of this observation revealed a decreased protein expression of a known tau splicing factor, htra2‐beta‐1 in AD, thereby implicating a trans mechanism. Our results demonstrate that dysregulation of combinatorial splicing might serve as a signature for aging‐related diseases, and the polony assay could be widely adapted for the study of other tauopathies. Furthermore, splicing‐based therapeutics is an emerging area of drug development, and a well‐defined and quantitative assay for monitoring single‐gene transcriptome will be relevant for such development.
- 26 July 2007
- Published by Wiley in Journal of Neurochemistry
- Vol. 103 (3) , 1228-1236
Single molecule profiling of tau gene expression in Alzheimer’s disease
Tau is a microtubule‐associated protein that is important for establishing and maintaining neuronal morphology. In addition to its role in normal cells, tau protein is involved in many neurodegenerative diseases, e.g. Alzheimer’s disease (AD) and frontotemporal dementia, as the main component of intraneuronal aggregates. Alternative splicing of tau gene in the brain can give rise to at least six protein variants. A causative role of skewed tau exon 10 inclusion has been defined in frontotemporal dementia; however, no link was established between the aberrant splicing of tau and AD. Here, we applied a single‐molecule‐based technology, polymerase colony or polony, to simultaneously monitor tau splicing variant and haplotype profile in sporadic AD and normal brains. We found that the coordinated expression of tau exons 2 and 10 is altered in AD. Additional investigations of cis and trans mechanisms of this observation revealed a decreased protein expression of a known tau splicing factor, htra2‐beta‐1 in AD, thereby implicating a trans mechanism. Our results demonstrate that dysregulation of combinatorial splicing might serve as a signature for aging‐related diseases, and the polony assay could be widely adapted for the study of other tauopathies. Furthermore, splicing‐based therapeutics is an emerging area of drug development, and a well‐defined and quantitative assay for monitoring single‐gene transcriptome will be relevant for such development.
- 1 June 2007
- Published by Elsevier in Molecular Cell
- Vol. 26 (5) , 753-767
MicroRNA-Mediated Feedback and Feedforward Loops Are Recurrent Network Motifs in Mammals
- 1 June 2007
- Published by Elsevier in Molecular Cell
- Vol. 26 (5) , 753-767
MicroRNA-Mediated Feedback and Feedforward Loops Are Recurrent Network Motifs in Mammals
- 17 July 2006
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 63 (18) , 2102-2118
Overlapping transcripts, double-stranded RNA and antisense regulation: A genomic perspective
Bioinformatic analysis of the transcriptomes of diverse eukaryotes has demonstrated the ubiquity and structural diversity of complementary antisense RNAs. These include both trans-encoded microRNAs and a large population of cis-encoded antisense RNAs that encompasses both coding and non-coding RNAs. Antisense regulation has previously been characterized primarily as a post-transcriptional response affecting RNA stability, nuclear processing, export, or translation. However, the formation of double-stranded (ds) RNAs by base-pairing between complementary RNAs may elicit regulatory responses at the transcriptional level as well. Analysis of antisense transcription at several imprinted loci has suggested a number of other mechanisms that may not require formation of dsRNA. Understanding the integration of transcriptional and post-transcriptional regulatory mechanisms represents a major challenge for understanding antisense regulation in eukaryotes. Such insight is also essential for understanding general principles of genetic regulation within the complex genomes characteristic of mouse and man as well as those of other eukaryotes.
- 17 July 2006
- Published by Springer Nature in Cellular and Molecular Life Sciences
- Vol. 63 (18) , 2102-2118
Overlapping transcripts, double-stranded RNA and antisense regulation: A genomic perspective
Bioinformatic analysis of the transcriptomes of diverse eukaryotes has demonstrated the ubiquity and structural diversity of complementary antisense RNAs. These include both trans-encoded microRNAs and a large population of cis-encoded antisense RNAs that encompasses both coding and non-coding RNAs. Antisense regulation has previously been characterized primarily as a post-transcriptional response affecting RNA stability, nuclear processing, export, or translation. However, the formation of double-stranded (ds) RNAs by base-pairing between complementary RNAs may elicit regulatory responses at the transcriptional level as well. Analysis of antisense transcription at several imprinted loci has suggested a number of other mechanisms that may not require formation of dsRNA. Understanding the integration of transcriptional and post-transcriptional regulatory mechanisms represents a major challenge for understanding antisense regulation in eukaryotes. Such insight is also essential for understanding general principles of genetic regulation within the complex genomes characteristic of mouse and man as well as those of other eukaryotes.